Efforts to scale and streamline gene and cell therapy production are intensifying with modular, automated bioprocessing platforms gaining traction. Ori Biotech’s flexible system integrates best-in-class technologies to accelerate manufacturing of CRISPR-edited T cells. ProBio opened a flagship U.S. plasmid and viral vector manufacturing GMP facility designed for cell and gene therapy programs’ clinical development and scale-up. These innovations aim to surmount manufacturing bottlenecks and meet growing clinical demand for advanced therapies.